Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

Leukemia. 2016 Apr;30(4):995-8. doi: 10.1038/leu.2015.225. Epub 2015 Aug 14.

Authors

S K Kumar¹, E Ma², A E Engebretson¹, F K Buadi¹, M Q Lacy¹, A Dispenzieri¹, M S Duh³, M-H Lafeuille³, P Lefebvre⁴, W Y Cheng³, K Dea⁴, D Rembert⁵, D Patt⁵, L Niculescu², M Quick², S V Rajkumar¹

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
² Millennium Pharmaceuticals Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA.
³ Analysis Group, Inc, Boston, MA, USA.
⁴ Groupe d'analyse, Ltée, Montreal, QC, Canada.
⁵ McKesson Specialty Health, The Woodlands, TX, USA.

PMID: 26271606
DOI: 10.1038/leu.2015.225

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / economics*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bortezomib / administration & dosage
Cyclophosphamide / administration & dosage
Dexamethasone / administration & dosage
Follow-Up Studies
Health Care Costs / statistics & numerical data*
Health Resources / statistics & numerical data*
Humans
Lenalidomide
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Multiple Myeloma / economics*
Multiple Myeloma / mortality
Neoplasm Staging
Prognosis
Survival Rate
Thalidomide / administration & dosage
Thalidomide / analogs & derivatives

Substances

Thalidomide
Bortezomib
Dexamethasone
Cyclophosphamide
Lenalidomide